SereNeuro raises oversubscribed pre-seed for non-opioid pain therapies
What's the deal? SereNeuro TherapeuticsDealroom has a profile for this one. Try Dealroom →, a preclinical-stage biotech based in Baltimore and Phoenix, has closed an oversubscribed pre-seed round. The capital advances its lead program, SN101, toward Investigational New Drug (IND)-enabling studies and supports a second program, SN102.
Who backed it? The syndicate included two Maryland-based venture firms and a physician investor. Qualifying investors structured their stakes through Maryland's Biotechnology Investment Incentive Tax Credit at the enhanced refundable rate available to companies in a federal Opportunity Zone, which covers SereNeuroDealroom has a profile for this one. Try Dealroom →'s East Baltimore site.
What's the endgame? SN101 is an off-the-shelf, non-opioid therapy made of purified human pain-sensing neurons derived from induced pluripotent stem cells. Delivered by a single injection into the affected joint, it is designed to relieve chronic pain while preserving joint structure, and has shown preclinical proof of concept.
The therapy emerged by accident. "It was never meant to be a drug," said co-founder Xinzhong Dong. "A joint pain model was available, and when we put the cells into the joint, we saw a therapeutic effect we had not set out to find. That observation became SN101."
What else? The second program, SN102, is a gene therapy for trigeminal neuralgia and other neuropathic pain. In September 2026, after the round closed, SereNeuro won its first NIH Small Business Innovation Research award, backing SN102 through the NIH HEAL Initiative, which targets the opioid crisis.
Why now? Non-opioid pain has become one of biotech's busiest corners this year, with an IPO, nine-figure financings, and pharma licensing deals. "Nearly all of it chasing one family of sodium channels for symptom relief," said chief executive officer Daniel Saragnese. "SereNeuro brings a different biology to the same problem."
SereNeuro says its neurons carry the full pain-channel identity of native human dorsal root ganglion neurons — Nav1.7, Nav1.8, and Nav1.9 — which most stem-cell-derived neurons lack.
The signal: Investor and government money is flowing into non-opioid pain as the field searches for alternatives to addictive painkillers. SereNeuro's bet is that living-cell therapy, rather than small-molecule channel blockers, can both relieve pain and protect tissue — a distinct approach in a crowded race.
Read more: pr.sandyjournal.com
Image credit: NIH-NCATS
